256 related articles for article (PubMed ID: 30848791)
1. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
[TBL] [Abstract][Full Text] [Related]
3. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.
Westberg-Rasmussen S; Starup-Linde J; Hermansen K; Holst JJ; Hartmann B; Vestergaard P; Gregersen S
Bone; 2017 Apr; 97():261-266. PubMed ID: 28126633
[TBL] [Abstract][Full Text] [Related]
5. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.
Skov-Jeppesen K; Veedfald S; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
Bone; 2021 Nov; 152():116065. PubMed ID: 34153529
[TBL] [Abstract][Full Text] [Related]
7. GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.
Skov-Jeppesen K; Svane MS; Martinussen C; Gabe MBN; Gasbjerg LS; Veedfald S; Bojsen-Møller KN; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
Bone; 2019 Aug; 125():178-185. PubMed ID: 31100534
[TBL] [Abstract][Full Text] [Related]
8. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
9. Effects of endogenous GIP in patients with type 2 diabetes.
Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
[TBL] [Abstract][Full Text] [Related]
10. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Helsted MM; Hansen LS; Hansen NL; Skov-Jeppesen K; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
Bone; 2023 May; 170():116687. PubMed ID: 36754130
[TBL] [Abstract][Full Text] [Related]
11. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
[TBL] [Abstract][Full Text] [Related]
12. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling.
Jensen NW; Clemmensen KKB; Jensen MM; Pedersen H; Færch K; Diaz LJ; Quist JS; Størling J
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579074
[TBL] [Abstract][Full Text] [Related]
13. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
[TBL] [Abstract][Full Text] [Related]
14. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
15. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis.
Lei WS; Kilberg MJ; Zemel BS; Rubenstein RC; Harris C; Sheikh S; Kelly A; Kindler JM
J Clin Transl Endocrinol; 2022 Dec; 30():100304. PubMed ID: 36110921
[TBL] [Abstract][Full Text] [Related]
16. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.
Skov-Jeppesen K; Christiansen CB; Hansen LS; Windeløv JA; Hedbäck N; Gasbjerg LS; Hindsø M; Svane MS; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1773-1780. PubMed ID: 38217866
[TBL] [Abstract][Full Text] [Related]
17. Incretin secretion in humans is under the influence of cannabinoid receptors.
Chia CW; Carlson OD; Liu DD; González-Mariscal I; Santa-Cruz Calvo S; Egan JM
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E359-E366. PubMed ID: 28655715
[TBL] [Abstract][Full Text] [Related]
18. Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.
Christensen MB; Lund AB; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
J Endocr Soc; 2020 Sep; 4(9):bvaa097. PubMed ID: 32904711
[TBL] [Abstract][Full Text] [Related]
19. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.
Thondam SK; Daousi C; Wilding JP; Holst JJ; Ameen GI; Yang C; Whitmore C; Mora S; Cuthbertson DJ
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E224-E233. PubMed ID: 28073779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
